The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects. This reduces time and money spent on sub optimal compounds and allows faster development of more efficacious new drugs. The company moved to purpose built laboratories at its current location in 2016 and continues to expand.
Pelago Bioscience AB
Spun out from the Karolinska Institute in 2013, Pelago Bioscience AB was founded to provide and develop the patented Cellular Thermal Shift Assay (CETSA) for use in determination and quantification of drug–target interactions.